Idioma:

Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy

Iannone, F ; Fanizzi, R ; Scioscia, C ; Anelli, MG ; Lapadula, G

Scandinavian journal of rheumatology, 2013-01, Vol.42 (1), p.41-44 [Periódico revisado por pares]

England: Informa Healthcare

Texto completo disponível

Citações Citado por

Enviar para

Título:
Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy
Autor: Iannone, F ; Fanizzi, R ; Scioscia, C ; Anelli, MG ; Lapadula, G
Assuntos: Adalimumab ; Adipose Tissue - drug effects ; Adult ; Aged ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal, Humanized - administration & dosage ; Antirheumatic Agents - administration & dosage ; Arthritis, Psoriatic - drug therapy ; Body Mass Index ; Cohort Studies ; Drug Resistance ; Etanercept ; Female ; Humans ; Immunoglobulin G - administration & dosage ; Infliximab ; Male ; Middle Aged ; Multivariate Analysis ; Receptors, Tumor Necrosis Factor - administration & dosage ; Remission Induction ; Retrospective Studies ; Tumor Necrosis Factor-alpha - antagonists & inhibitors
É parte de: Scandinavian journal of rheumatology, 2013-01, Vol.42 (1), p.41-44
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Objectives: There is evidence that fat tissue may influence the response to therapy in patients with arthritis. The aim of this study was to assess whether the body mass index (BMI) affects rates of clinical remission in patients with psoriatic arthritis (PsA) treated with anti-tumour necrosis factor (TNF)-α biological drugs. Method: We retrospectively studied 135 patients with active peripheral PsA (45 obese, 47 overweight, and 43 normal-weight). Baseline BMI was correlated with the clinical response to adalimumab, etanercept, or infliximab. After 36 months (median, range 6-79) of treatment, disease remission rates were assessed using the Disease Activity Score in 28 joints (DAS28) or the Simplified Disease Activity Index (SDAI). Possible predictors of clinical outcomes were assessed by multivariate analysis. Results: At baseline, BMI was significantly correlated only with the Health Assessment Questionnaire (HAQ) score (r = 0.21, p = 0.02) and not with disease activity. BMI did not predict disease remission or changes in HAQ score following anti-TNF-α therapy. Obese patients showed a significantly higher HAQ score and took significantly lower doses of prednisone than normal-weight or overweight patients, but their disease remission rates on the DAS28 (37%) or the SDAI (21%) were not significantly different from those of the other two groups (44% and 21%, respectively), regardless of the TNF-α inhibitor prescribed. Conclusions: In our retrospective analysis, disease activity and clinical response to anti-TNF-α therapy in PsA do not seem to be affected by BMI. Further prospective studies are needed to confirm these preliminary results.
Editor: England: Informa Healthcare
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy

Iannone, F ; Fanizzi, R ; Scioscia, C ; Anelli, MG ; Lapadula, G

England: Informa Healthcare

Buscando em bases de dados remotas. Favor aguardar.